After initial symptoms and tests, NET was the first diagnosis for these results will help drive the most common diagnostic tools that led to correct diagnosis were biopsy in the UK, every fourth NET patient received diagnosis in a medical center globally, 44% (1043/2359) of patients were initially misdiagnosed at least 20% overall, 2795 participants SCAN assessed global delivery of access to specialized NET diagnosis during Sept 30 global (11% [253/2359]) and in IE (9% [24/119]; NS; Figure 2) mean time to correct diagnosis for patients misdiagnosed was similar: Global: 4.75 years (N = 1043); UK: 4.4 (N=148); IE: 5.24 (N=46) almost half of patients had stage IV NETs at diagnosis (Global: 46% [1077/2359]; UK: 45% [126/279]; IE: 41% [49/119]; Figure 2)

Figure 2: Misdiagnosis and staging of NETs

Figure 3: Type of hospital where NET diagnosis was received

Figure 4: Diagnostic tool leading to correct NET diagnosis

CONCLUSIONS

• SCAN represents the largest global compendium of data about NETs' extent
• Misdiagnosis and the extremely high proportion of NET patients diagnosed with stage IV, which is associated with poorer patient outcomes, remain global challenges
• The experiences of UK and Irish patients on their route to diagnosis is similar to that of patients surveyed worldwide
• Access to specialized NET centers should be improved for all NET patients and more HCPs knowledgeable in NETs are needed
• These results will help drive forward optimal care and referral pathways to achieve the goal of earlier diagnosis
• This survey further contributes to positioning NET research on an equal footing with other cancers of similar prevalence

REFERENCES


ACKNOWLEDGEMENTS

INCA would like to thank all its members as well as its partners: ENETS (European Neuroendocrine Tumor Society), NANETS (North American Neuroendocrine Tumor Society), APNETS (Asia-Pacific Neuroendocrine Tumor Society), CommNETs (Commonwealth Neuroendocrine Tumor Group), JNETS (Japan Neuroendocrine Tumor Society), CNETS (Chinese Neuroendocrine Tumor Society), UICC (Union for International Cancer Control), EUORDIS (European Organisation for Rare Diseases), NORD (National Organization for Rare Disorders) and ECOO (European Cancer Organisation) and many others for their instrumental support of this global effort. INCA would also like to thank its industry supporters: Ipsen, ITM and Novartis.

Strategen Ltd, Winchester, UK provided editorial support to the authors.

FUNDING AND DISCLOSURES

This study was industry sponsored. The authors have nothing to declare.